European-based Unilabs has deployed the SOPHiA
DDM™ Platform across its network in Switzerland to support cancer diagnostics and
treatment
BOSTON and ROLLE,
Switzerland, April 17,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company and a leader in data-driven
medicine, today announced that Unilabs, one of the largest
diagnostic providers in Europe,
and the only provider to offer laboratory, imaging and pathology
specialties within one group, is live on the SOPHiA DDM™
Platform. Unilabs will use SOPHiA GENETICS' technology to test
for HRD-status in solid tumors and provide expedited analysis
across its network in Switzerland.
Founded in 1987 in Switzerland,
Unilabs conducts more than 221 million tests annually across its
laboratories, imaging centers, and collection centers. A leader in
diagnostics, Unilabs continues to grow and expand its business to
offer cutting-edge diagnostic services enabled by leading
technologies and platforms, such as the SOPHiA DDM™ Platform.
The implementation of SOPHiA GENETICS' technology across
Switzerland will support the
company's ability to offer leading testing and analysis to its
customer-base and help further the use of precision medicine.
"SOPHiA GENETICS' AI-based technology is at the forefront of
where precision medicine is going – blending science and technology
to deliver the best possible outcomes for patients. The addition of
the SOPHiA GENETICS Platform to our suite of offerings will support
our effort to deliver the fastest and most accurate diagnostics to
our patients," said Mattia Schmid,
PhD., FAMH, Scientific Manager, Unilabs.
HRD is caused by a cell's impaired ability to repair DNA
double-stranded breaks through the homologous recombination repair
(HRR) pathway and is the most prevalent alteration in ovarian
cancer1 with approximately half of all newly diagnosed
patients having HRD-positive tumors2.
HRD in a tumor is an important predictor of tumor response to
certain treatment options, however, to detect HRD, researchers
often use next-generation sequencing (NGS), which can produce a
complex data set that is time-intensive and costly to analyze. The
SOPHiA DD Platform uses Artificial Intelligence (AI) and
machine learning with patented technologies to analyze and
interpret raw NGS data, providing reliable and fast HRD results
that can help guide treatment planning.
"As a diagnostics leader, Unilabs is responsible for delivering
fast and accurate testing results to patients throughout
Europe each year, and our team at
SOPHiA GENETICS is proud to be one of the technology leaders
helping to enable these results," said Kevin Puylaert, Managing
Director, EMEA, SOPHiA GENETICS. "Identifying HRD-status is key to
facilitating the use of precision medicine among ovarian cancer
patients worldwide. The implementation of the SOPHiA DDM™ Platform
will support Unilabs as it continues to offer the very best in
testing and diagnostics to all of Europe."
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.com or connect on X,
LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products, and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X, LinkedIn, Facebook, and Instagram. Where others
see data, we see answers.
SOPHiA DDM™ Dx HRD Solution is available as a CE-IVD product
for In Vitro Diagnostic Use in Europe and Turkey. The information in this press release
is about products that may or may not be available in different
countries and, if applicable, may or may not have received approval
or market clearance by a governmental regulatory body for different
indications for use. Please contact support@sophiagenetics.com to
obtain the appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
1
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342032/#:~:text=According%20to%20The%20Cancer%20Genome,clinical%20benefits%20of%20PARP%20inhibitors.
2 https://www.sciencedirect.com/science/article/pii/S0923753421048286
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-unilabs-is-using-its-ai-technology-to-detect-homologous-recombination-deficiency-hrd-302118997.html
SOURCE SOPHiA GENETICS